<?xml version="1.0" encoding="UTF-8"?>
<p>Antiviral candidates such as azvudine, baloxavir marboxil, favipiravir, remdesivir, ribavirin and umifenovir are being tested for COVID-19 (
 <xref ref-type="fig" rid="F2">figure 2</xref>) [
 <xref rid="C162" ref-type="bibr">162</xref>, 
 <xref rid="C180" ref-type="bibr">180</xref>â€“
 <xref rid="C182" ref-type="bibr">182</xref>]. Remdesivir is a nucleotide analogue showing 
 <italic>in vitro</italic> activity against SARS-CoV-2 [
 <xref rid="C182" ref-type="bibr">182</xref>]. Remdesivir is being studied in two large phase 3 RCTs (
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link>: NCT04252664 and NCT04257656), of which one multicentre trial conducted in Hubei, China, in severe COVID-19 showed no difference in time to clinical improvement or mortality benefit [
 <xref rid="C183" ref-type="bibr">183</xref>]. Umifenovir has shown 
 <italic>in vitro</italic> activity against SARS-CoV-1 [
 <xref rid="C184" ref-type="bibr">184</xref>] and improved radiological findings when added to lopinavir/ritonavir in a small RCT [
 <xref rid="C185" ref-type="bibr">185</xref>], and seems suitable for further development.
</p>
